Investors

Rekah is a public company traded on the Tel Aviv Stock Exchange (REKA). As of February 2015, the company is jointly controlled by FIMI Opportunity Funds and the Elgrably family.

FIMI, the leading private equity firm in Israel, has a track record of success spanning over 20 years that includes, to date:

  • 86 investments
  • 56 exits with a total value over $4.5B
  • 6 private equity funds
  • Over $3B in assets under management
  • Global top ranking as the most consistent performing fund manager

News

Document of Principles Signed

A binding document of principles was signed between Rekah’s subsidiary Vitamad and Teva Pharmaceuticals. Teva will transfer the manufacturing rights for several prescription drugs, OTC drugs and hospital antiseptic products to Vitamed, which will supply them exclusively to Teva.

Innovative Agreement Signed

An innovative agreement was signed between the Rekah’s subsidiary Bela Online and Leumit HMO, for the supply of medicines, cosmetics and paramedical products to the homes of Leumit members.

Marketing Authorizations

Rekah’s subsidiary Vitamed received Marketing Authorizations in Israel for four antibiotic injections.